QIAGEN N.V. to Report Third Quarter and First Nine Months of 2016 Results

VENLO, the Netherlands, October 11, 2016 /PRNewswire/ --

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the third quarter and first nine months of 2016 on Wednesday November 2, at approximately 21:00 Central European Time (CET) / 16:00 Eastern Time (ET). (The release time in Europe is one hour earlier than usual due to Europe having already switched to winter time before the U.S.)  

On the same day, a conference call is planned for 22:00 Central European Time (CET) / 17:00 Eastern Time (ET) that will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference Call & Webcast Details 

For the conference call on Wednesday, November 2, interested parties may listen to the call by dialing: +1 631 302 6547 (U.S.), +44 203 059 8128 (UK), +49 69 566 036 000 (Germany). The webcast will be accessible at www.qiagen.com/de/about-us/investors/corporate-calendar.

A conference call replay will be available through November 9, 2016, by dialing:

+1 724 5589 653 (U.S.), +44 121 260 4861 (UK), +49 69 710 488 70 (Germany) (passcode: 238087#).

Contact: IR@qiagen.com

About QIAGEN 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com

Contact:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 11711
+1-240-686-2222
Email: ir@qiagen.com

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com

SOURCE QIAGEN N.V.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.